Economy/Home · Economy

[Breaking] Samchundang Pharm Starts at Upper Limit in Pre-Market NXT... Soars 29.82% — Afternoon Session Extension in Focus

Samchundang Pharm (000250) opened at the upper price limit on the July 20 trading session, the first after the Constitution Day holiday and weekend, driven by s

Oseong Kwon
Staff Reporter
4 min read
[Breaking] Samchundang Pharm Starts at Upper Limit in Pre-Market NXT... Soars 29.82% — Afternoon Session Extension in Focus
CBC News

Samchundang Pharm (000250) opened at the upper price limit on the July 20 trading session, the first after the Constitution Day holiday and weekend, driven by strong buying interest from the pre-market Nextrade (NXT) session. The robust upward momentum has continued into the regular trading session, drawing intense market attention.

As of 8:50 a.m. on July 20, Samchundang Pharm's share price stood at 239,000 won, up 54,900 won (+29.82%) from the previous session. Investors are closely watching whether the sharp rally will be sustained until the afternoon session closes.

As this marks the first trading day after the domestic stock market experienced significant volatility, it is also being viewed as a testing ground to gauge changes in individual stock supply and demand as well as the recovery of investor sentiment. In particular, some analysts note that Samchundang Pharm has exhibited high price volatility recently, making it necessary to examine both the background of today's surge and the increase in trading volume. They project that the short-term stock price trajectory could vary depending on whether the early-session strength extends into the afternoon or a wave of profit-taking sell orders emerges.

Meanwhile, investors are also focused on how domestic and external variables accumulated over the Constitution Day holiday and weekend will be reflected in today's market. While volatility centered on tech stocks continues in the U.S. stock market, there is speculation that sector-specific divergent trends may emerge in the domestic market as well. Attention is converging on whether Samchundang Pharm's upper-limit trend will extend into the afternoon session.

[※ Investors are solely responsible for their investment decisions, and it is essential to review relevant disclosures and company fundamentals before investing.]

Oseong Kwon
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.